论文部分内容阅读
The excellent efficacy of the oral epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) erlotinib in the patients with symptomatic brain metastases from an EGFR-mutant lung adenocarcinoma were previously reposed.